抗中性粒细胞胞质抗体相关血管炎疾病活动度、ANCA类型与血脂水平的关系
本研究基于Rituximab for ANCA-Associated Vasculitis(RAVE)试验的142份储存血清样本,比较基线与第6个月的血脂变化。结果显示新诊断及PR3-ANCA阳性患者的总胆固醇、低密度脂蛋白和载脂蛋白B升高,而复发疾病或MPO-ANCA阳性患者无此变化;利妥昔单抗与环磷酰胺组间无差异。
要点
- 新诊断AAV及PR3-ANCA阳性患者诱导缓解期血脂升高。
- 复发疾病或MPO-ANCA阳性患者未见血脂升高。
- 血脂变化与红细胞沉降率变化相关,与其他炎症指标或糖皮质激素暴露无关。
核心结论
- 新诊断AAV和PR3-ANCA阳性患者在缓解诱导期血脂水平升高,评估血脂谱时应考虑疾病活动度和ANCA类型以分层CVD风险。
研究设计与样本
- 基于RAVE试验储存血清样本(基线与第6个月)的血脂评估,采用配对t检验和多变量线性回归分析,共142例患者有可用血清样本。
主要发现
- 总胆固醇升高+12.4 mg/dl(95%CI +7.1, +21.0),低密度脂蛋白升高+10.3 mg/dl(95%CI +6.1, +17.1),载脂蛋白B升高+3.5 mg/dl(95%CI +1.0, +8.3)。
- 上述变化见于新诊断和PR3-ANCA阳性患者,未见於复发疾病或MPO-ANCA阳性患者。
- 利妥昔单抗组与环磷酰胺组血脂变化无差异。
- 血脂变化与红细胞沉降率变化相关,与其他炎症标志物或糖皮质激素暴露无关。
关键数值与推荐
- 142例患者平均年龄52.3±14.7岁,男性72例(51%),PR3-ANCA阳性95例(67%),新诊断AAV 72例(51%),接受利妥昔单抗75例(53%)。
临床怎么用
- 对AAV患者评估血脂谱和CVD风险时,应结合疾病活动度与ANCA类型进行分层,尤其关注新诊断及PR3-ANCA阳性患者。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have an elevated risk of cardiovascular disease (CVD). This study was undertaken to develop a clearer understanding of the association between changes in disease activity and lipid levels in AAV, which may inform CVD risk stratification in this population. METHODS: Lipid levels were assessed in stored serum samples (obtained at baseline and month 6) from the Rituximab for ANCA-Associated Vasculitis (RAVE) trial, which randomized patients to receive either rituximab or cyclophosphamide followed by azathioprine. Paired t-tests and multivariable linear regression were used to assess changes in lipid levels. RESULTS: Of the 142 patients with serum samples available, the mean ± SD age was 52.3 ± 14.7 years, 72 (51%) were male, 95 (67%) were proteinase 3 (PR3)-ANCA positive, 72 (51%) had received a new diagnosis of AAV, and 75 (53%) were treated with rituximab. Several lipid levels increased between baseline and month 6, including total cholesterol (+12.4 mg/dl [95% confidence interval (95% CI) +7.1, +21.0]), low-density lipoprotein (+10.3 mg/dl [95% CI +6.1, +17.1]), and apolipoprotein B (+3.5 mg/dl [95% CI +1.0, +8.3]). These changes were observed among newly diagnosed and PR3-ANCA-positive patients but not among those with relapsing disease or myeloperoxidase-ANCA-positive patients. There was no difference in change in lipid levels between rituximab-treated patients and cyclophosphamide-treated patients. Changes in lipid levels correlated with changes in erythrocyte sedimentation rate but not with other inflammatory markers or glucocorticoid exposure. CONCLUSION: Lipid levels increased during remission induction among patients with newly diagnosed AAV and those who were PR3-ANCA positive. Disease activity and ANCA type should be considered when assessing lipid profiles to stratify CVD risk in patients with AAV.
引用
- Wallace ZS, Fu X, Liao K, et al. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019. PMID: 31162829. doi:10.1002/art.41006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。